Spotlight
About
News
CME/CE
Subscribe
Partnerships
Low-dose SSRI formulation shows promise for vasomotor symptoms
A new formulation of a selective serotonin receptor inhibitor (SSRI)-low-dose mesylate of paroxetine (LDMP)-shows promise for reducing vasomotor symptoms of menopause, according to results of two studies presented at the North American Menopause Society (NAMS) conference.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Recent Videos
Related Content
